Skip to content

Akari Therapeutics Plc

AKTX· NasdaqCore metricsCIK 1541157

Pharmaceutical preparations552 peers

Last sale
Nov 12, 2026 · -10.43%
Market cap
$1.27T
186.09B shares
Filings
747
$0.00
—
—
-$4.84M
Q3 2026N/M FY25 yoy
-$4.68M
Q3 2026N/M FY25 yoy
-$4.76M
—derivedN/M FY19 yoy
$0.00
Q3 2026
$5.74M
Q3 2026
$1.27T
—
—
72567.5×
—
—

FY2025 figures · derived

Price

$6.83+997.27%+$6.20past year
Nov 12, 2026 · IEX last sale
Figure
Range
IEX last saleClose of recordAs traded

Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Financials

Revenue

$0.00—
No annual history for this metric yet.
PeriodEndedValueKindSource trail

Segments

Geography
Long-lived assets by Geography, FY2019 to FY2022FY2019United Kingdom · FY2019 · $3.19KUnited States · FY2019 · $1.82KFY2020FY2021FY2022
LineFY2022ShareChange
United Kingdom$0.00——
United States$0.00——
Total$0.00

From the 20-F filed May 1, 2023AKTX

Pharmaceutical preparations

Akari Therapeutics Plc is the 2nd largest of the 553 covered companies the SEC files under this code, by market cap. SIC 2834

Peers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in market cap first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.

Akari Therapeutics Plc · CIK 1541157 · Engraved from SEC EDGAR